Virology And Transmission
Viral Characteristics
- Single-stranded RNA virus.
- Classified within Flaviviridae family.
- Comprises six major genotypes (1-6) and numerous subtypes.
- High RNA polymerase error rate produces multiple viral variants (quasispecies).
- Quasispecies generation facilitates evasion of host immune surveillance.
Transmission Dynamics
- Vertical (mother-to-infant) transmission represents primary acquisition route in pediatric population.
- Vertical transmission risk approximates 5-7% per pregnancy.
- Concomitant maternal human immunodeficiency virus (HIV) infection or high maternal viral load (>3,000,000 IU/mL) elevates vertical transmission risk to 20%.
- Horizontal transmission routes include intravenous drug use, contaminated blood products (rare post-1992 screening), and high-risk sexual contact.
- Breastfeeding does not increase transmission risk; contraindicated only if maternal HIV coinfection exists.
Clinical Manifestations
Acute Infection
- Insidious onset; predominantly asymptomatic or mild clinical course.
- Fulminant hepatic failure exceptionally rare.
- Incubation period ranges 2 to 24 weeks (mean 7-9 weeks).
Chronic Infection And Extrahepatic Signs
- Chronic infection defined by detectable viral ribonucleic acid (RNA) persisting >6 months.
- 20-40% of infected children achieve spontaneous sustained viral clearance within first 5 years of life.
- Remaining majority progress to chronic infection.
- Cirrhosis, hepatic failure, and hepatocellular carcinoma represent major long-term morbidities developing over 20-30 years.
- Extrahepatic manifestations occur; include essential mixed cryoglobulinemia, membranoproliferative glomerulonephritis, cutaneous vasculitis, porphyria cutanea tarda, and lichen planus.
Diagnostic Evaluation
Age-Specific Testing Protocols
Maternal antibodies undergo passive transplacental transfer, persisting up to 18 months postnatally, confounding early serologic screening.
| Patient Age | Diagnostic Modality | Interpretation And Rationale |
|---|---|---|
| <18 Months | Quantitative HCV RNA polymerase chain reaction (PCR). | Requires positive testing on two separate occasions after 2 months of age to confirm infection. Anti-HCV IgG unreliable due to maternal antibody persistence. |
| >18 Months | Anti-HCV IgG (enzyme immunoassay). | Initial screening tool. High false-positive rate in low-risk populations. Does not confer immunity. |
| >18 Months | Quantitative HCV RNA PCR. | Confirmatory test following positive antibody screen. Differentiates active from resolved infection; monitors treatment response. |
Management Protocol
Direct-Acting Antiviral (DAA) Therapy
- Goal of therapy: Sustained viral response (SVR), defined as undetectable HCV RNA 12 to 24 weeks following treatment cessation.
- SVR correlates with improved histology and halted disease progression.
- DAAs replaced highly toxic, poorly tolerated interferon/ribavirin regimens.
- DAAs safely approved for pediatric patients 3 years of age.
- Achieve SVR rates >95% in pediatric cohorts.
DAA Pharmacological Classes
Regimens combine distinct classes targeting specific viral life cycle proteins to prevent drug resistance.
| DAA Class | Suffix | Mechanism Of Action |
|---|---|---|
| NS3/4A Protease Inhibitors | ”-previr” (e.g., Glecaprevir) | Inhibits viral polyprotein processing. |
| NS5A Inhibitors | ”-asvir” (e.g., Velpatasvir) | Blocks viral replication and assembly. |
| NS5B Polymerase Inhibitors | ”-buvir” (e.g., Sofosbuvir) | Inhibits HCV RNA replication. |
Preferred Regimens
Recent advancements utilize pangenotypic agents, eliminating necessity for preliminary genotype testing.
- Sofosbuvir-Velpatasvir: Administered once daily for 12 weeks.
- Glecaprevir-Pibrentasvir: Administered for 8 weeks.
Surveillance And Prognosis
- Infected patients require regular screening with abdominal ultrasonography and serum alpha-fetoprotein to monitor for hepatocellular carcinoma.
- Mandate vaccination against Hepatitis A and B to prevent severe superimposed hepatic injury.
- DAA therapies facilitate viral eradication before irreversible fibrotic or cirrhotic damage occurs, yielding excellent long-term prognosis.